Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients

Hypertension
Carmine SavoiaE L Schiffrin

Abstract

Some antihypertensive agents may improve resistance artery remodeling in hypertensive patients whereas other agents may not, for similar blood pressure reduction. We questioned whether the selective mineralocorticoid receptor blocker eplerenone improves resistance artery remodeling in hypertensive patients versus the beta-blocker atenolol. Sixteen hypertensive patients were randomly assigned to double-blind daily treatment with eplerenone or atenolol. Resistance arteries from gluteal subcutaneous tissue were assessed on a pressurized myograph. After 1 year of treatment, systolic and diastolic blood pressures were similarly well controlled in both groups. Endothelial function did not change with treatment in either group. Media/lumen ratio and cross-sectional area were unchanged in either the atenolol or the eplerenone group. In atenolol-treated patients, the arterial wall became stiffer, whereas in the eplerenone-treated patients, it became less stiff and similar to that of a normotensive control group. The media collagen/elastin ratio was reduced only after eplerenone treatment. Circulating concentrations of osteopontin, monocyte chemoattractant protein-1, basic fibroblast growth factor, interleukin-8, and interleukin-10 were ...Continue Reading

References

Feb 1, 1994·American Journal of Hypertension·D RizzoniE Agabiti-Rosei
Feb 15, 2002·Journal of Vascular Research·Erik N T P BakkerEd VanBavel
Oct 5, 2002·Hypertension·Agostino VirdisErnesto L Schiffrin
Oct 18, 2002·American Journal of Physiology. Heart and Circulatory Physiology·Ricardo RochaJohn A Delyani
Dec 31, 2002·Cardiovascular Research·Karen A DetillieuxPeter A Cattini
Apr 2, 2003·The New England Journal of Medicine·Bertram PittUNKNOWN Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators
Oct 15, 2003·Circulation·Damiano RizzoniEnrico Agabiti-Rosei
Jun 11, 2005·Heart Failure Reviews·Hylton V Joffe, Gail K Adler
Jan 25, 2006·Hypertension·Ernesto L Schiffrin
Mar 3, 2006·Bioorganic & Medicinal Chemistry·Ana GomesEduarda Fernandes
Apr 25, 2007·Hypertension·Stéphane Laurent, Pierre Boutouyrie
May 1, 2007·Journal of the American Society of Hypertension : JASH·Rhian M TouyzErnesto L Schiffrin

❮ Previous
Next ❯

Citations

Jul 16, 2008·Current Diabetes Reports·Ho Won LeeNathaniel Winer
Apr 29, 2010·Current Hypertension Reports·Enrico Agabiti-Rosei, Damiano Rizzoni
Jun 2, 2010·Current Hypertension Reports·Asia Rehman, Ernesto L Schiffrin
Jun 5, 2010·Current Hypertension Reports·Cheryl L Laffer, Fernando Elijovich
Feb 1, 2011·Current Hypertension Reports·Marie Briet, Ernesto L Schiffrin
May 30, 2008·Journal of Human Hypertension·M E SafarE Agabiti-Rosei
Mar 18, 2010·Nature Reviews. Nephrology·Marie Briet, Ernesto L Schiffrin
Feb 19, 2009·Proceedings of the National Academy of Sciences of the United States of America·Youngtae JeongCharles J Lowenstein
May 11, 2012·Cardiology in Review·Tanja Dudenbostel, Stephen P Glasser
Dec 31, 2009·Current Opinion in Nephrology and Hypertension·Ana M BrionesMercedes Salaices
Feb 24, 2010·Circulation·Bradley A Maron, Jane A Leopold
Jul 21, 2010·Hypertension·Srinivasa Raju Datla, Kathy K Griendling
Oct 20, 2011·Cardiovascular Diabetology·Markus ReschDierk H Endemann
Oct 22, 2010·Circulation Journal : Official Journal of the Japanese Circulation Society·Hae-Young Lee, Byung-Hee Oh
Jul 10, 2013·Vascular Health and Risk Management·Jason L GuichardMustafa I Ahmed
May 1, 2012·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Charalambos KoumarasAsterios Karagiannis
Jun 2, 2012·World Journal of Cardiology·Nikolaos LionakisMaria Georgopoulou
Jun 19, 2013·American Journal of Hypertension·Asako MiyakiRyuichi Ajisaka
Aug 30, 2014·BioMed Research International·Miodrag JanićMišo Sabovič
Jun 12, 2009·Journal of Hypertension·Pieter M JansenAnton H van den Meiracker
Mar 19, 2009·Journal of Hypertension·Enrico Agabiti-RoseiDamiano Rizzoni
Aug 6, 2009·Journal of Hypertension·Eyal LeibovitzErnesto L Schiffrin
Mar 16, 2012·Journal of Hypertension·Carmine Savoia, Guido Grassi
Nov 23, 2012·Journal of Vascular Research·Marie Briet, Ernesto L Schiffrin
Jun 22, 2012·The Canadian Journal of Cardiology·Omar de RitaJ David Spence
Feb 11, 2012·Journal of the American Society of Hypertension : JASH·Dylan Burger, Rhian M Touyz
Oct 22, 2011·Journal of the American Society of Hypertension : JASH·Federico Cacciapuoti
Apr 28, 2016·The Canadian Journal of Cardiology·Adam HarveyRhian M Touyz
Oct 6, 2009·Trends in Endocrinology and Metabolism : TEM·Maria-Christina ZennaroBruno Fève
Nov 22, 2008·Steroids·Alex Odermatt, Atanas G Atanasov
Jun 27, 2008·Trends in Pharmacological Sciences·Chiara MarchesiErnesto L Schiffrin
Sep 24, 2015·Journal of Hypertension·Agnes JumarRoland E Schmieder
Sep 13, 2008·Cardiovascular Therapeutics·Xinkang WangGiora Z Feuerstein
Feb 26, 2013·Journal of Renal Care·Rebecca SandsPaul R Kalra
Sep 3, 2011·Basic & Clinical Pharmacology & Toxicology·Damiano RizzoniEnrico Agabiti Rosei
Jan 28, 2014·European Journal of Heart Failure·Javaid IqbalFaiez Zannad
Jun 10, 2014·European Journal of Clinical Investigation·Labrini PapanastasiouGeorge Piaditis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.